Port Macquarie, NEW%20SOUTH%20WALES1 Active Studies

Multiple Myeloma Clinical Trials in Port Macquarie, NEW%20SOUTH%20WALES

Find 1 actively recruiting multiple myeloma clinical trials in Port Macquarie, NEW%20SOUTH%20WALES. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
440
Enrolling

Recruiting Multiple Myeloma Studies in Port Macquarie

About Multiple Myeloma Clinical Trials in Port Macquarie

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 1 multiple myeloma clinical trials recruiting participants in Port Macquarie, NEW%20SOUTH%20WALES. These studies are seeking a combined 440 participants. Research is being sponsored by AbbVie. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Port Macquarie — FAQ

Are there multiple myeloma clinical trials in Port Macquarie?

Yes, there are 1 multiple myeloma clinical trials currently recruiting in Port Macquarie, NEW%20SOUTH%20WALES. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Port Macquarie?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Port Macquarie research site will contact you about next steps.

Are clinical trials in Port Macquarie free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Port Macquarie studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 1 active trials in Port Macquarie are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated March 2, 2026 from ClinicalTrials.gov